American Diabetes Association
cd22-0693 KidsAP_Consortium_.pdf (102.25 kB)

Cambridge hybrid closed-loop system in very young children with type 1 diabetes reduces caregivers’ fear of hypoglycemia and improves their well-being.

Download (102.25 kB)
posted on 2022-10-04, 21:23 authored by Carine de Beaufort, Ulrike Schierloh, Ajay Thankamony, Julia Ware, Malgorzata E Wilinska, Elke Fröhlich-Reiterer, Thomas M. Kapellen, Birgit Rami‐Merhar, Sabine E. Hofer, Fiona M. Campbell, James Yong, Laura E. Bocchino, Judy Sibayan, Julia Lawton, Stéphane Roze, Maria Fritsch, Alena Thiele, Janet M Allen, Charlotte Boughton, Julia K. Mader, Craig Kollman, Roman Hovorka, Ineke M. Pit-ten Cate, KidsAP Consortium


Objective To evaluate the impact of CamAPS FX hybrid closed-loop automated insulin delivery (HCL) in very young children with type 1 diabetes (T1D) on caregivers’ well-being, fear of hypoglycemia and sleepiness.

Research Design Multinational, open label, randomized crossover study. Children (1-7years) with T1D received treatment for two 4-month periods in random order, comparing HCL with sensor augmented pump (SAP) (control). At baseline and after each treatment period, caregivers were invited to complete WHO-5, Hypoglycemia Fear Survey (HFS) and Epworth Sleepiness Scale (ESS). 

Results Caregivers of 74 children (mean±SD: age 5±2 years; 42% female, baseline HbA1c 7.3±0.7%) participated. Results revealed significantly lower scores for hypoglycemia fear (p<.001) and higher for well-being (p<.001) after HCL treatment. A trend towards a reduction in sleepiness score was observed (p=0.09). 


Our results suggest a better well-being and less hypoglycemia fear in caregivers of very young children with T1D on CamAPS FX HCL. 


European Commission > Horizon 2020 Framework Programme 731560


National Institute for Health Research Cambridge Biomedical research Centre

Wellcome Strategic Award x 100574/Z/12/Z


Usage metrics

    Diabetes Care


    Ref. manager